Back to industrial propertyImmunotherapy considerably improved cancer treatment and yielded durable therapeutic responses in many cancer subtypes. The presence of tumour-infiltrating lymphocytes (TILs) plays a determinant role in cancer progression, and abundant infiltration of Natural Killer (NK) cells correlates with better patient outcomes. Yet, only 20 to 40% of patients respond to immune-modulating therapies. Growing evidence underscores the fundamental role of the tumour microenvironment (TME) in enhacing immunosuppressive signalling and interfering with cytotoxic immune cell infiltration in the tumour mass.The present invention is related to the field of cell biology and biomedicine, more precisely to cell culture systems and cell culture methods which allow to effectively recapitulate the organisation and composition of the stroma, including fibroblast and fibroblast-derived extracellular matrix found at the interface of solid tumours and around tissues and organs.
